Cargando…

Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir

Detalles Bibliográficos
Autores principales:	Francisci, D, Falcinelli, E, Belfiori, B, Petito, E, Mezzasoma, M, Baldelli, F, Gresele, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113067/ http://dx.doi.org/10.1186/1758-2652-13-S4-P62

Ejemplares similares

Platelet activity in HIV-infected patients on abacavir-containing antiretroviral therapy
por: Palacios, R, et al.
Publicado: (2010)

Response to treatment of hepatitis C in HCV/HIV co-infected patients is not influenced by either abacavir or tenofovir with weight-based ribavirin
por: Bhatti, L, et al.
Publicado: (2010)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
por: Rasmussen, Thomas A, et al.
Publicado: (2011)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Nitric oxide protects against HIV gp120 endothelial injury
por: Fiorucci, S, et al.
Publicado: (2010)

Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway
por: Bury, Loredana, et al.
Publicado: (2021)

Epidemiological features, therapeutic strategies and long-term immunological outcomes in virologically suppressed HIV+ very late presenters
por: Martinelli, L, et al.
Publicado: (2010)

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children
por: Gitta, PK, et al.
Publicado: (2010)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine
por: Brar, Indira, et al.
Publicado: (2020)

Tenofovir use is associated with low vitamin D levels in a Spanish HIV cohort
por: Cervero, M, et al.
Publicado: (2010)

Intracellular tenofovir-diphosphate accumulation in an HIV-infected patient with Fanconi syndrome and osteomalacia
por: Haverkort, ME, et al.
Publicado: (2010)

Evaluation of a pharmacogenetic test in Thailand for abacavir hypersensitivity screening in human immunodeficiency virus infection
por: Chonlaphat, Sukasem, et al.
Publicado: (2014)

1614. Efficacy and Safety of Adjusted Renal Dosing of Tenofovir DF Versus Abacavir Switching in HIV Patients with Decreased Glomerular Filtration Rate After Receiving Tenofovir DF-Based Regimen
por: Yamasmith, Eakkawit, et al.
Publicado: (2023)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data
por: Rodriguez, Allan E, et al.
Publicado: (2010)

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
por: Ross, L. L., et al.
Publicado: (2010)

Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2012)

Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Martin, Allison, et al.
Publicado: (2011)

Learning the Ropes of Platelet Count Regulation: Inherited Thrombocytopenias
por: Bury, Loredana, et al.
Publicado: (2021)

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States
por: Dorjee, Kunchok, et al.
Publicado: (2021)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen
por: Wikman, P, et al.
Publicado: (2010)

Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial
por: Rasmussen, Thomas A., et al.
Publicado: (2012)

Hip Structural Parameters over 96 Weeks in HIV-Infected Adults Switching Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2014)

Infrequent, low magnitude HIV-specific T cell responses in HIV-uninfected participants in the 1% tenofovir microbicide gel trial (CAPRISA004)
por: Burgers, WA, et al.
Publicado: (2012)

A p.Arg127Gln variant in GPIbα LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD
por: Bury, Loredana, et al.
Publicado: (2022)

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort
por: Cuzin, L, et al.
Publicado: (2010)

Kidney tubular function and serum phosphate levels in HIV-1-infected patients treated with tenofovir: preliminary results
por: Grima, P, et al.
Publicado: (2010)

Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir
por: Padilla, Authors: Sergio, et al.
Publicado: (2011)

Intestinal complications associated with cardiovascular surgical procedures
por: Mastoraki, S, et al.
Publicado: (2007)

Chemical modification of the 6'-amino cyclopropyl of abacavir eliminates HLA-B*57:01-restricted CD8+ T-cell activation without loss of antiviral activity
por: Alhaidari, Mohammad, et al.
Publicado: (2014)

HLA Alleles Association with Changes in Bone Mineral Density in HIV-1-Infected Adults Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2014)

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function
por: Guillemi, Silvia A, et al.
Publicado: (2016)

Effect of First Long-Term Training on Whole Blood Count and Blood Clotting Parameters in Thoroughbreds
por: Miglio, Arianna, et al.
Publicado: (2021)

Toxic intracellular anabolite levels of tenofovir and didanosine causing a steep CD4-cell decline
por: de Jong, E, et al.
Publicado: (2010)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jvd9keatpdrulbthdftlabj0cb